Zoetis Inc (ZTS) FinancialsZTSZoetis Inc

Zoetis Inc (ZTS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Parasiticides, accounting for 28.3% of total sales, equivalent to $698.00M. Other significant revenue streams include Vaccines and Dermatology. Understanding this composition is critical for investors evaluating how ZTS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Zoetis Inc maintains a gross margin of 71.64%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 40.80%, while the net margin is 28.00%. These profitability ratios, combined with a Return on Equity (ROE) of 64.91%, provide a clear picture of how effectively ZTS converts its operational activities into shareholder value.

In the context of the broader market, ZTS competes directly with industry leaders such as ALNY and BIIB. With a market capitalization of $31.96B, it holds a significant position in the sector. When comparing efficiency, ZTS's gross margin of 71.64% stands against ALNY's 76.88% and BIIB's 65.46%. Such benchmarking helps identify whether Zoetis Inc is trading at a premium or discount relative to its financial performance.

Zoetis reported Q2 revenue of $2.5 billion, with a gross margin of 71.64% and a net margin of 28.00%. The forward P/E ratio is 12.5, indicating reasonable valuation compared to growth prospects.